UNIPRINT.NET
12.4.2016 15:49:48 CEST | Business Wire | Press release
UniPrint.net Corp , industry leader in printing virtualization technology, today announces the release of 3 print appliances – UniPrint Infinity™ vPad Pro, vPad Touch, and vPad CE . The multi-purpose, printer-vendor independent appliances are designed to enable on demand printing with security, and low maintenance and high speed remote printing across offices and geo locations, while the UniPrint Infinity printing software is in use. UniPrint Infinity vPads can also replace remote site or branch Windows print servers, making the process of consolidation into the data center much simpler, and ongoing IT support costs of remote print servers a thing of the past.
With the advent of cloud technology, an increasing number of organizations are moving to consolidate their data centers, be it on-premises or off-premises, in an effort to reduce IT support costs, provide centralized administration, and secure data and printer access. Yet remote print servers have remained a burden to manage and a challenge to support, especially when combined with frequent changes and updates, causing remote print speed issues and security implications for businesses with dispersed locations.
These industry-first vPads feature dual security via 256 bit encryption, user-authenticated print release, and print stream compression which reduces print data sizes by up to 95%, promoting fast data transmission and printing at remote sites . They can also act as remote print server gateway devices, eliminating the need to procure and support Windows hardware and software in remote locations.
“These simple, plug and play devices are game changers. They help to unleash the true power of the UniPrint Infinity software, allowing enterprise users to print in an unprecedentedly secure and speedy way. The 3 models allow the customers to have the best choice and within budget,” noted UniPrint.net Chief Technical Officer Arron Fu.
The vPads can provide support to multiple printers and are compatible with any computing environment. Installation is a straightforward plug and play, and no configuration is required by any personnel in the remote site.
For further information on UniPrint Infinity and vPads, or to download a free product trial, please visit www.uniprint.net or email sales@uniprint.net . Alternatively, sign up for our free 30-minute webinar “Do you Really Need Remote Print Servers?” April 21, 2016 at 1:00 PM U.S. Eastern Standard Time.
About UniPrint.net
UniPrint.net is the recognized leader in printing virtualization. The newest solution in UniPrint’s patented, award-winning product line, UniPrint Infinity v9 is the industry’s first truly secure enterprise-wide solution for any computing environment. Enabling anywhere, anytime, any device secure pull printing, UniPrint Infinity comes with proven ROI through its statistics module, print document archiving functionality and secure mobile printing modules, and high availability with load balancing. UniPrint Infinity replaces all manufacturer printer drivers with a single PDF generator to promote faster, more efficient printing, helping organizations to improve both productivity and return on investments.
UniPrint and UniPrint Infinity are the trademarks of UniPrint.net. All other trademarks and registered trademarks are properties of their respective owners.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160412006028/en/
Contact:
UniPrint.net
Katherine Cheung, Marketing Manager, +1 416-503-9800
ext. 8566
katherine.cheung@uniprint.net
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom